Drugs in ATC Class L04AK

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L04 - IMMUNOSUPPRESSANTS

Up to L04A - IMMUNOSUPPRESSANTS

Drugs in ATC Class: L04AK - Dihydroorotate dehydrogenase (DHODH) inhibitors

Tradename	Generic Name
ARAVA	leflunomide
LEFLUNOMIDE	leflunomide
AUBAGIO	teriflunomide
TERIFLUNOMIDE	teriflunomide

Market dynamics and patent landscape for ATC Class L04AK (DHODH inhibitors)

Last updated: June 11, 2026

Executive summary: ATC L04AK DHODH inhibitors sit at the intersection of immunology and autoimmune drug discovery, with a patent landscape dominated by small-molecule core chemistry, specific substitution patterns, crystal forms/solid-state variants, and dosing regimens. Near- and mid-term market dynamics are driven by (1) how fast sponsors can convert clinical differentiation into IP-coverable claims (formulations and methods of treatment), (2) geographic filing and enforcement strategy, and (3) whether competing candidates share overlapping chemical matter such that generic entry becomes encumbered by hard-to-design-around patents. A durable estate typically requires layered coverage: active-ingredient composition of matter plus at least one defensive “thickness layer” in polymorphs/co-crystals and therapeutic uses, which materially increases the odds of successful regulatory exclusivity-by-patent or settlement-based delayed launches even when early chemistry patents expire.

Which DHODH inhibitors define the ATC L04AK market and competitive set?

Featured snippet answer: ATC L04AK is built around dihydroorotate dehydrogenase (DHODH) inhibitors as targeted immunomodulators. The market is structured by (i) late-stage, market-facing candidates with strong composition-of-matter and solid-state portfolios, and (ii) earlier-stage programs where patent breadth and defensibility hinge on substitution-defined chemistry and crystalline form strategy.

How is ATC L04AK typically occupied by DHODH inhibitor drug candidates?

DHODH inhibitors are primarily positioned in autoimmune and inflammatory disease indications. The commercial set is typically composed of:

• Oral small-molecule DHODH inhibitors (most programs in this class are oral kinase-analog style small molecules targeting DHODH).
• Indication clusters in rheumatology, dermatology, and inflammatory lung disease (depending on the sponsor’s clinical readouts).
• A patent strategy that tracks the “chemistry-to-variant-to-use” playbook: broad compounds early, then narrower improvements via polymorphs, salts, solvates, and treatment regimens.

What market dynamics matter most for DHODH inhibitors?

Key dynamics that influence pricing power, uptake, and the IP-to-revenue conversion rate:

• Route of administration: oral dosing enables faster switching from biologics in some settings but increases the importance of formulation IP (solid-state form, dissolution, bioavailability).
• Safety/tolerability profile: DHODH inhibition can create class-specific adverse-effect constraints that often lead to dose optimization patents and method-of-treatment claims.
• Mechanism differentiation: sponsors that can tie target engagement to clinically defined endpoints strengthen method-of-use claims and can resist design-around around the core compound.

What patents protect dihydroorotate dehydrogenase (DHODH) inhibitors?

Featured snippet answer: Patent coverage for L04AK DHODH inhibitors generally concentrates in four layers: (1) composition of matter for the DHODH inhibitor core compounds, (2) sub-structure-defined analogs that broaden or narrow the claim scope, (3) solid-state forms and process-by-design manufacturing patents, and (4) methods of treatment, including dose regimens and specific patient populations.

1) Composition-of-matter: core DHODH inhibitor chemistry

Composition-of-matter claims usually cover:

• DHODH inhibitory compounds defined by heterocycles and substitution patterns.
• Specific linker and ring substitutions that optimize potency and selectivity against related enzymes.

Business implication: If the leading compound has a broad scaffold claim family, generic developers focus on bypassing claimed analogs through different heterocycles or substitution patterns. If the estate is narrow but dense with close analog patents, circumvention becomes more expensive.

2) Solid-state: polymorphs, solvates, hydrates, amorphous forms, co-crystals

Solid-state patents are a common defensive layer because:

• DHODH inhibitors can exist in multiple crystalline forms depending on milling, solvent, and crystallization conditions.
• Improved stability, hygroscopicity control, and dissolution can be tied to patient outcomes and bioavailability.

Business implication: Even with an expiring core chemistry patent, ongoing solid-state patent coverage can block generic substitution if FDA approval depends on demonstrating sameness only within the same solid-state “family” or if the generic chooses a form still covered by claims.

3) Manufacturing and process patents

Process claims typically include:

• Steps for synthesis of the key intermediate and coupling chemistry.
• Crystallization and purification parameters that yield a protected form.
• Scale-up or specific solvent systems.

Business implication: Process patents can delay generic entry through manufacturing constraints and can trigger supply-side settlements if a generic cannot produce a non-infringing solid-state form cheaply.

4) Methods of treatment and dosing regimens

Methods include:

• Indications aligned to clinical trials.
• Dosing frequency and dose-escalation protocols.
• Patient stratification where claims reference response markers or disease severity.

Business implication: Method-of-use patents can extend effective exclusivity even after compound patents expire, depending on how sponsors draft claims and how generics pursue “carve-out” label strategies.

How many patents cover L04AK DHODH inhibitors, and what is the coverage density?

Featured snippet answer: Coverage density for DHODH inhibitors is typically concentrated in a handful of claim families that repeat across jurisdictions: a core compound family, a variant/solid-state family, and at least one treatment regimen family. The effective “count” can be high because each family generates multiple filings and continuations, but the practical blocking power comes from families that align with the marketed formulation and labeled dosing.

Coverage density drivers

• Jurisdictional breadth (US, EP, UK, JP, CN, KR, IN can multiply total filings).
• Continuation strategy (continuations, divisionals, and continuation-in-part can add layers within the same priority chain).
• Formulation specificity: one marketed product can inherit multiple protected solid-state variants and release profiles.

What to look for in real-world estates

A strong DHODH estate typically shows:

• Multiple granted claims (not only pending).
• Claims explicitly tied to the marketed dose form (tablet/capsule) and its solid-state properties.
• Explicit linkage between the compound and a clinical dose range.

When does DHODH inhibitor exclusivity end, and what dates govern generic timing?

Featured snippet answer: For small-molecule DHODH inhibitors, exclusivity timing in practice is governed by the earlier of (i) composition-of-matter patent expiry and (ii) any granted formulation or method-of-use patents still in-force, plus the potential impact of regulatory exclusivities such as data exclusivity and patent term adjustments. The “generic launch clock” is usually the final in-force blocking patent that a Paragraph IV challenge would target.

How to map exclusivity to the patent expiration stack

A typical stack for a marketed DHODH inhibitor includes:

• Compound composition-of-matter expiration (often the earliest large barrier to generic entry).
• Solid-state form patent expiration (can trail composition-of-matter by a few years depending on filings and grant schedules).
• Method-of-use regimen expiration (can extend the label strategy constraints).
• Any terminal disclaimers or PTA/PTA offsets (jurisdiction dependent).

What drives the effective delay beyond nominal expiry?

• Settlement agreements that impose “pay-for-delay” style non-entry timelines (when litigation leads to a settlement).
• Enforcement in multiple jurisdictions where clinical supply is regionally fragmented.
• Generic design-around failure due to formulation immaterial differences.

What generic entry risks exist for DHODH inhibitors under Paragraph IV?

Featured snippet answer: Paragraph IV risk is highest when the estate is “thin” on solid-state and method-of-use patents. It is lower when the marketed product is protected by an overlapping solid-state and dosing regimen claim family that a generic cannot avoid without changing the product beyond what is acceptable for label substitution.

How Paragraph IV challenges typically attack DHODH estates

Generic challengers often file Paragraph IV certifications that:

• Challenge claims as obvious/anticipated.
• Argue non-infringement by selecting a different solid-state form or different substitution pattern.
• Attempt to carve out specific indications, doses, or patient subgroups if method-of-use claims are narrow but label-relevant.

What usually blocks “easy” generic substitution

• Patent claims on specific polymorphs or co-crystals that are used in the commercial drug substance.
• Treatment regimen claims that are aligned with labeling dosage and frequency.
• Manufacturing/process claims that prevent a generic from reproducibly manufacturing the same variant cheaply.

What is the Orange Book status of DHODH inhibitors?

Featured snippet answer: The Orange Book status matters because it ties FDA-listed patents to the specific NDA/BLA and product strength and dosage form. For DHODH inhibitors, the critical Orange Book items are typically formulation and method-of-use patents tied to the marketed presentation, not just broad chemistry composition claims.

How to interpret Orange Book listings for market entry planning

• Patent type mapping: US patents listed under Orange Book typically include composition, method-of-use, and sometimes formulation or product-related patents.
• Expiry by listed patent: effective risk is the latest listed patent that a generic would need to clear to market.
• Patent-jurisdiction alignment: if other jurisdictions have later expiry, a “cleared US” product can still face delay regionally.

What patent litigation affects DHODH inhibitors and how does it shape settlement risk?

Featured snippet answer: Patent litigation for DHODH inhibitors typically determines the settlement-based launch timing by identifying which claim families are strongest for infringement and which can survive validity challenges. The most market-relevant litigation is that which centers on the specific marketed solid-state/formulation and labeled dosing regimen.

Typical litigation pathways

• ANDA Paragraph IV: challenges to listed patents tied to the specific NDA.
• Injunction actions: attempts to block launch based on infringement of active patents.
• Claim construction disputes: frequently decisive for solid-state/formulation claims with technical limitations.

What settlements usually do in DHODH cases

• Delay generic launch until a particular claim expires.
• Provide “design-around” workarounds if the generic can produce a non-infringing form.
• Sometimes include licensing terms that allow earlier entry with constraints on dosing or formulation.

How do DHODH inhibitors compare on patent strength: which estates are most defensible?

Featured snippet answer: The most defensible DHODH inhibitor estates combine broad core chemistry with at least one high-value defensive layer in solid-state and method-of-use claims aligned to labeling. Estates that rely only on core composition-of-matter with fewer product-linked variants are more vulnerable to design-around through alternative analogs or non-infringing solid-state forms.

Comparison framework for investors and BD

A usable scoring model (qualitative-to-quantitative):

• Breadth: number of granted claims covering compound scaffold and substitution space.
• Product linkage: explicit protection of the marketed solid-state form used in tablets/capsules.
• Regimen linkage: whether method-of-use claims track labeled dosing and endpoints.
• Litigation track record: history of surviving validity challenges or prevailing in enforcement.
• Continuation density: whether claim families continue to mature with grant activity through time.

What formulations are protected for DHODH inhibitors, and why does it matter for generics?

Featured snippet answer: Formulation patents for DHODH inhibitors usually protect the commercial solid-state form (polymorph/co-crystal/solvate), dissolution characteristics, and sometimes tablet/capsule composition and manufacturing conditions that ensure consistent bioavailability. These patents make generic substitution harder because even if the active ingredient scaffold is non-infringing, the marketed product’s solid-state properties may still be covered.

Where formulation protection typically appears

• Drug substance patents: polymorph/co-crystal and hydrate/solvate forms.
• Drug product patents: excipient systems, tablet/capsule composition, and manufacturing methods.
• Stability patents: shelf-life improvements tied to packaging or humidity stability.

What method-of-use patents protect DHODH inhibitors, and when do they expire?

Featured snippet answer: Method-of-use claims for DHODH inhibitors generally cover labeled indications and sometimes specific patient populations and dosing regimens. Expiry depends on filing date and whether continuations or divisionals were used, but the most material risk for generics comes from method-of-use claims that match the label for which the ANDA seeks approval.

Method-of-use claim patterns

• Indication-specific claims (disease name, severity criteria).
• Dose range and frequency claims (e.g., once-daily vs twice-daily schedules).
• Combination therapy claims (DHODH inhibitor plus another immunomodulator), which can constrain carve-out approaches.

Which companies are likely challenging DHODH inhibitor patents, and what is the competitive launch risk?

Featured snippet answer: Patent challenge activity typically comes from established generic players and from value-seeking challengers with ANDA portfolios. The key launch risk is whether challengers can clear the last in-force Orange Book-listed patent that maps to product formulation and dosing, not just the earliest core compound expiry.

Competitive launch risk categories

• High risk: estate ends on composition-of-matter with weak solid-state coverage.
• Medium risk: strong formulation IP but narrower method-of-use claims.
• Low risk: multi-layer overlap across core chemistry, multiple solid-state forms, and labeled dosing/method-of-use claims that are difficult to design around.

How do licensing deals and settlements affect DHODH inhibitor market share?

Featured snippet answer: For DHODH inhibitors, licensing and settlements can determine whether challengers enter via earlier “authorized generics,” co-development deals, or carve-outs that avoid direct conflict with formulation and regimen patents. These outcomes can shift market share without fully changing the competitive patent landscape.

Settlement-driven market structures

• Authorized generics: license to launch under constraints.
• Carve-out labels: limited indication entry pending method-of-use expiry.
• Technology transfer: generic can manufacture a non-infringing solid-state variant under a cross-license.

What geographic patent coverage matters most for DHODH inhibitors?

Featured snippet answer: The highest enforcement value is usually in jurisdictions where (i) the marketed product is sold and (ii) patent claim families are thick across composition, solid-state, and use. For most global portfolios, enforcement focus is typically US plus major EU markets, then targeted expansions into Japan and other regions depending on sales and regulatory timeline.

Where to focus for launch-blocking analysis

• US: Orange Book mapping and Paragraph IV risk.
• EP/UK: litigation venue and SPC availability where relevant.
• JP: often significant for solid-state enforcement strategy.
• CN/IN: where local filing density can change generic entry timing.

Key takeaways

1. DHODH inhibitor estates in ATC L04AK are strongest when layered: core composition plus solid-state and method-of-use claims aligned to the commercial product.
2. Generic timing is driven by the last in-force blocking patent on the Orange Book stack, not the nominal expiry of the earliest composition-of-matter family.
3. Formulation patents on polymorphs/co-crystals and process patents create the highest design-around friction for ANDA challengers.
4. Litigation outcomes and settlements tend to lock launch timing to expiry of specific product-linked claim families.
5. Geographic enforcement strategy determines the real-world ability to delay market entry even when a challenger clears one jurisdiction.

FAQs

1. What solid-state patents most often block generic DHODH inhibitors?
2. How do method-of-use (indication and dosing) claims change ANDA label design for DHODH inhibitors?
3. What is the typical filing strategy timeline from DHODH core discovery to polymorph and regimen patents?
4. When do DHODH inhibitor SPCs (if any) become the dominant timing driver in Europe?
5. What litigation claim constructions most frequently decide infringement for DHODH inhibitor solid-state/formulation patents?

References

1. European Medicines Agency. (n.d.). European public assessment reports and information on data/exclusivity framework. EMA.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book databases. FDA.
3. World Intellectual Property Organization. (n.d.). Patent law and priority/filing concepts used in pharmaceutical patent families. WIPO.